• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 5:08:07 PM ET
    $BXRX
    Misc Health and Biotechnology Services
    Health Care
    Get the next $BXRX alert in real time by email
    SC 13G 1 d8805012_13g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Baudax Bio, Inc.
    (Name of Issuer)

     

     

    Common Stock, par value $0.01
    (Title of Class of Securities)

     

     

    07160F107
    (CUSIP Number)

     

     

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)

     

    [_] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     

    CUSIP No 07160F107    

       

         
    1. NAME OF REPORTING PERSONS  
         
      Armistice Capital, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,343,469  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,343,469  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,343,469  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.99%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
     

    IA, OO

     

     
     
     

     

     

    CUSIP No 07160F107    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Steven Boyd  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,343,469  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,343,469    
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,343,469    
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.99%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
     

    IN, HC

     

     
     
     

     

     

    CUSIP No 07160F107    

     

           
    Item 1. (a). Name of Issuer:  
           
        Baudax Bio, Inc.  
           
      (b). Address of Issuer's Principal Executive Offices:  
           
       

    490 Lapp Road

    Malvern, Pennsylvania 19355

    United States of America

     
           
           
    Item 2. (a). Name of Person Filing:  
           
       

    Armistice Capital, LLC

    Steven Boyd

     
           
      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     
           
      (c) Citizenship:  
           
       

    Armistice Capital, LLC – Delaware

    Steven Boyd – United States of America

     
           
      (d).   Title of Class of Securities:  
           
        Common Stock, par value $0.01  
     

     

     

       
      (e). CUSIP Number:  
           
        07160F107  

     

     


    Item 3.
      If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
           
      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [X] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     
     

     

     
    Item 4. Ownership.
     
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a)   Amount beneficially owned:
         
       

    Armistice Capital, LLC – 4,343,469

    Steven Boyd – 4,343,469

         
      (b)   Percent of class:
         
       

    Armistice Capital, LLC – 9.99%

    Steven Boyd – 9.99%

         

     

      (c)   Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote    
         

     

    Armistice Capital, LLC – 0

    Steven Boyd – 0

     

     
        (ii)   Shared power to vote or to direct the vote    
         

     

    Armistice Capital, LLC – 4,343,469

    Steven Boyd – 4,343,469

      

     
        (iii) Sole power to dispose or to direct the disposition of    
         

     

    Armistice Capital, LLC – 0

    Steven Boyd – 0

     

     
        (iv)   Shared power to dispose or to direct the disposition of    
         

     

    Armistice Capital, LLC – 4,343,469

    Steven Boyd – 4,343,469

     
                 

      

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
       
      N/A
     
     

     

     

     

     
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      Armistice Capital Master Fund Ltd., a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, LLC, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
       

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
      If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
     

     

     

    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
     

     

     

    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A
     

     

     

    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 16, 2021
      (Date)

     

     

      Armistice Capital, LLC
       
      By:  /s/ Steven Boyd
      Steven Boyd
      Managing Member
     

     

     

      /s/ Steven Boyd
      Steven Boyd

     

     

     

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     
     

     

    Exhibit A

    AGREEMENT

     

    The undersigned agree that this Schedule 13G dated February 16, 2021 relating to the Common Stock, par value $0.01, of Baudax Bio, Inc. shall be filed on behalf of the undersigned.

     

      Armistice Capital, LLC
       
      By:  /s/ Steven Boyd
      Steven Boyd
      Managing Member
     

     

     

      /s/ Steven Boyd
      Steven Boyd

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $BXRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BXRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Mcandrew Natalie

      3 - Baudax Bio, Inc. (0001780097) (Issuer)

      10/11/23 4:47:44 PM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 3: New insider Kim Yong Chan claimed ownership of 202,260 shares

      3 - Baudax Bio, Inc. (0001780097) (Issuer)

      7/13/23 4:21:37 PM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 4: Henwood Geraldine bought $3,057 worth of shares (1,200 units at $2.55), increasing direct ownership by 98% to 2,427 units

      4 - Baudax Bio, Inc. (0001780097) (Issuer)

      12/19/22 8:09:42 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care

    $BXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)

      SC 13G/A - Baudax Bio, Inc. (0001780097) (Subject)

      2/14/24 10:25:34 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)

      SC 13G/A - Baudax Bio, Inc. (0001780097) (Subject)

      2/6/24 11:12:01 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)

      SC 13G/A - Baudax Bio, Inc. (0001780097) (Subject)

      7/10/23 5:12:03 PM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care

    $BXRX
    SEC Filings

    See more
    • SEC Form 8-K filed by Baudax Bio Inc.

      8-K - Baudax Bio, Inc. (0001780097) (Filer)

      2/28/24 6:15:52 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 25-NSE filed by Baudax Bio Inc.

      25-NSE - Baudax Bio, Inc. (0001780097) (Subject)

      2/15/24 8:53:22 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio Inc. filed SEC Form 8-K: Other Events

      8-K - Baudax Bio, Inc. (0001780097) (Filer)

      12/12/23 9:52:05 PM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care

    $BXRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Cosette Pharmaceuticals Appoints Rick Casten as CFO Amid Transformational Growth

      Experienced financial executive will build on growth trajectory Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, today announced the appointment of Rick Casten as Chief Financial Officer (CFO), bolstering its executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005044/en/Rick Casten, SVP and Chief Financial Officer, Cosette Pharmaceuticals (Photo: Business Wire) "I am excited to have Rick Casten join our team, with his more than two decades of experience in helping drive long term performance gains and financial growth. Rick joins Cosette at a pivotal inflection point

      7/6/22 8:15:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio Strengthens Management Team with Appointment of Richard S. Casten as Chief Financial Officer

      MALVERN Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the appointment of Richard S. Casten, CPA, MBA as Chief Financial Officer. In this role, Mr. Casten will be responsible for leading and directing the financial activities of the Company. Mr. Casten brings to Baudax 25 years of diversified financial experience across pharmaceutical, Fortune 500 consumer products and public accounting. He replaces Ryan D. Lake, CPA who is transitioning to full time Chief Financial Officer for Recro. “I am delighted to welcome Richard to the Baudax team and believe his expertise and leadersh

      3/8/21 7:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care

    $BXRX
    Financials

    Live finance-specific insights

    See more
    • Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

      MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on September 5, 2023. The shares of Series C Preferred Stock will be distri

      8/23/23 8:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio Acquires TeraImmune, Inc.

      TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax Baudax Bio CEO Gerri Henwood to Serve as CEO of Combined Entity MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) --  Baudax Bio, Inc. (NASDAQ:BXRX) ("Baudax Bio" or the "Company"), a pharmaceutical company focused on innovative products for acute care and related settings, today announced the acquisition of TeraImmune, a privately held a biotechnology company focused on discovery and development of novel Treg-based cell therapies for autoimmune diseases. "This combination blends the world class scientific expertise of the TeraImmune team with

      6/30/23 8:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio Announces Date of Reconvened Annual Meeting

      MALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on innovative products for acute care and related settings, recently announced that it has adjourned its Annual Meeting of Shareholders (the "Annual Meeting") without any business being conducted, due to lack of shareholder participation resulting in a failure to reach required quorum. The Annual Meeting will reconvene at 9:00 a.m. Eastern time on June 23, 2023 and will continue to be held virtually at www.virtualshareholdermeeting.com/BXRX2023. The record date for determining shareholders eligible to vote at the Special Meeting will remain the close of business

      6/6/23 9:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care

    $BXRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Baudax Bio Announces Corporate Update

      Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024 MALVERN, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that following recent shareholder approval of corporate actions related to

      10/18/23 8:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors

      MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. TI-168 is the Company's next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors.

      9/28/23 8:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care
    • Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference

      MALVERN, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory T cells ("Tregs"), as well as a portfolio of clinical stage Neuromuscular Blocking Agents ("NMBs") and an associated reversal agent, today announced that that the Company's management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13, 2023 in New York, NY. Gerri Henwood, President & Chief Executive Officer of Baudax Bio, will give a pre-recorded presentation highlighting the Company's cellular therapy progra

      9/7/23 8:00:00 AM ET
      $BXRX
      Misc Health and Biotechnology Services
      Health Care